维生素d及其受体与乙型肝炎病毒相关性肝细胞肝癌的关系

《维生素d及其受体与乙型肝炎病毒相关性肝细胞肝癌的关系》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位巧妈１００８９料或巾刖１３２９１Ｗ？度钟Ａ多ＨｅｂｅｉＭｅｄｉｃａｌＵｎｉｖｅｒｓｉｔｙ硕±学位论文在职科学学位维生素Ｄ及其受体与芭型肝炎病毒相关性肝细胞肝癌的关系学位申请人；李玉聲导师：赵彩彥教授专业：内科学二级学院：第Ｈ医院２０１５年１０月河北医科大学学位论文使用援巧及知识产权归属承谱本学位论文在导师，由本人独立完成。（或指导小組）的指导下本学位论文巧究巧获得的研究成果，其知识产权归河北医科大學所有。河化医科大学有

2、权对本学检论文迸行交流、公开巧使用。凡发表一与学位论文主要内容相关的论文，，第署名为单位河化医科大学试验材鲜、原始数据、申报的专利等知识产权均归河北陵科大学所有，巧则，承捏相应法律责任，研究生签名；＾导师签葦级学院＾章气巧化慶科大学研究生学位论文独创性声明本论文是在导师指导下迸行的硏巧工作及取得的研究成果，除了文中特别加Ｗ标注和致谢等內容外，文中不包舍其他人邑经发表或撰写的研究成果，指导教师对此进巧了审定。本论文由本人独立撰写。，文责自负研究生签名：导师签聲’ｆ年＞

3、７ｉ＾月日２＾目录中文摘要·················································································1英文摘要·················································································4研究论文维生素D及其受体与乙型肝炎病毒相关性肝细胞肝癌的关系前言········································

4、·········································7材料与方法········································································8结果···············································································17附图······················································

5、·························18附表···············································································21讨论···············································································22结论································································

6、···············26参考文献·········································································27综述维生素D及受体与肝细胞肝癌研究进展·································30致谢·····················································································39个人简历················

7、······························································40中文摘要维生素D及其受体与乙型肝炎病毒相关性肝细胞肝癌的关系摘要目的：肝癌(livercancer)是指发生在肝脏的恶性肿瘤，依据肝癌来源分为原发性肝癌和转移性肝癌两种，其中肝细胞肝癌(hepatocellularcarcinoma，HCC，简称肝癌)占原发性肝癌的90％。HCC是目前世界第五大常见肿瘤之一，位列第二位的癌症死亡原因，每年大约有一百万人死于HCC，其中大约50%发生在中国

8、，具有较高的发病率和病死率；在我国80%的HCC患者有乙型肝炎病毒（hepatitisBvirus，HBV）或丙型肝炎病毒（hepatitisCvirus，HCV）感染基础，发病隐匿，早期临床症状不明显，诊断率较低；大多数患者确诊时，病情已经发展到中晚期，失去手术治疗机会，而且HCC生物恶性程度较高，5年生存率低，预后欠佳。目前HCC仍是慢性病毒性肝炎、肝硬化患者的主要死